Results 11 to 20 of about 5,312,533 (302)
Bladder Cancer: Current Challenges and Future Directions
Medicina, 2021 Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era ...
J. Dobruch, M. Oszczudlowski
semanticscholar +1 more source
European Urology Open Science, 2023 Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response.
Evangelia Vlachou +6 more
doaj +1 more source
Nature Reviews Disease Primers, 2023 Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease.
Lars Dyrskjøt +6 more
openaire +2 more sources
Annals of Urologic Oncology, 2021 Introduction To evaluate the response of patients with high-risk bacillus Calmette-Guerin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) who we treated with intravesical CG0070, a conditionally replicating granulocyte macrophage colony ...
Evan Austin +3 more
doaj +1 more source
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection
Scientific Reports, 2023 Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of BC but this remains largely ...
L. Baxter +14 more
doaj +1 more source
Cancer Research, 2022 The RNA N6-methyladenosine (m6A) writer methyltransferase-like 3 (METTL3) is upregulated in many types of cancer and promotes cancer progression by increasing expression of several oncogenes. Therefore, a better understanding of the mechanisms regulating
Z. Ni +11 more
semanticscholar +1 more source
Oncology and Therapy, 2023 In this plain language podcast, highlights from the European Society for Medical Oncology (ESMO) Congress are discussed for a second year in a row, from the perspective of both a patient advocate and a healthcare professional.
Alex Filicevas, Thomas Powles
doaj +1 more source
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca, 2020 Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has primarily consisted of platinum‐based chemotherapy.
V. Patel, W. Oh, M. Galsky
semanticscholar +1 more source
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Molecular Cancer, 2022 The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhenjun Shi +18 more
semanticscholar +1 more source
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2020 This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and ...
T. Flaig +34 more
semanticscholar +1 more source